In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 1, 2000, Pages 109-113

  Schmitz, Franz Josef ^a,b   Fluit, Ad C ^b   Milatovic, Dana ^b   Verhoef, Jan ^b   Heinz, Hans Peter ^a   Brisse, Sylvain ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; METICILLIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SITAFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; GENE LOCUS; GENE MUTATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; DRUG EFFECT; GENETICS; HUMAN; MICROBIOLOGICAL EXAMINATION; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 0033911192     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.1.109     Document Type: Article

References (10)

1. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
2. Gootz, T. D. & McGuirk, P. R. (1994). New quinolones in development. Expert Opinion on Investigational Drugs 3, 93-114.
3. Schmitz, F.-J., Hofmann, B., Hansen, B., Scheuring, S., Lückefahr, M., Klootwijk, M. et al. (1998). Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 41, 481-4.
4. Geisel, R., Schmitz, F.-J., Thomas, L., Berns, G., Zetsche, O., Ulrich, B. et al. (1999). Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. Journal of Antimicrobial Chemotherapy 43, 846-8.
5. Schmitz, F.-J., Köhrer, K., Scheuring, S., Verhoef, J., Fluit, A., Heinz, H.-P. et al. (1999). The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 5, 287-90.
6. Schmitz, F.-J., Fluit, A. C., Lückefahr, M., Engler, B., Hofmann, B., Verhoef, J. et al. (1998). The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 42, 807-10.
7. Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S. et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-3.
8. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
9. Neyfakh, A. A., Borsch, C. M. & Kaatz, G. W. (1993). Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrobial Agents and Chemotherapy 37, 128-9.
10. Schmitz, F.-J., Hertel, B., Hofmann, B., Scheuring, S., Verhoef, J., Fluit, A. et al. (1998). Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains. Journal of Antimicrobial Chemotherapy 42, 561-3.